Empire Biotechnologies is developing an orally delivered, protein therapeutic called Mfge8 to treat diseases of malabsorption. Our long-term vision is a therapy for the millions suffering from malabsorption; our current focus is the orphan disease Short Bowel Syndrome (SBS). SBS patients suffer from debilitating malnutrition, and treatments are extremely limited, demonstrating a significant unmet need.
Short bowel syndrome
Short Bowel Syndrome (SBS) is the most severe condition of malabsorption. SBS occurs when a gastrointestinal disease becomes so severe it requires surgical removal of the affected portion and resection of the remaining intestine. This drastic decrease in intestinal surface area greatly reduces nutritional intake and causes severe malabsorption. Consequently, patients with SBS suffer from physical weakness, chronic diarrhea, dehydration, and often develop serious psychological issues due to the drastic lifestyle changes necessary to cope with SBS.
the mfge8 solution
Empire Biotechnologies is developing an orally delivered, therapeutic protein (Mfge8) capable of significantly increasing the absorption of nutrients in the intestine. This endogenous integrin ligand is found highly concentrated in breast milk. Mfge8 works two-fold by increasing fat uptake directly in intestinal epithelial cells, while simultaneously slowing gastric motility, thus increasing the time for nutrient absorption. Because of these two complementary mechanisms of action, this protein promises to be highly effective in treating malabsorption and can drastically improve the quality of life for patients who suffer from SBS.